Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University , Bangkok , Thailand.
Research and Development Institute, Government Pharmaceutical Organization , Bangkok , Thailand.
Hum Vaccin Immunother. 2019;15(10):2440-2445. doi: 10.1080/21645515.2019.1638205. Epub 2019 Sep 5.
Being vigilant of the potential for an influenza pandemic, the Global Action Plan for Influenza Vaccines (GAP) promoted the establishment and maintenance of local vaccine manufacturing capacity. In accordance with this, the Thai government has developed its national strategic plan for influenza pandemic preparedness including the plan for manufacturing influenza vaccine in Thailand. With the support of WHO, the Thai Government Pharmaceutical Organization (GPO) as the developed local production capacity of influenza vaccines. The H1N1 live attenuated influenza vaccine (LAIV) and H5N2 LAIV produced by GPO have been proven to be safe and immunogenic through clinical trials, followed by Thai FDA licensure for pandemic use. The GPO-produced H5N2 LAIV has been proven to have priming effects on an inactivated subunit H5N1 booster vaccine. This Thai local manufacturer is now expanding its capacity to Inactivated Influenza Vaccine (IIV), aiming for sustainable influenza vaccine production for national coverage.
警惕流感大流行的潜在威胁，全球流感疫苗行动计划（GAP）推动了当地疫苗生产能力的建立和维护。根据这一计划，泰国政府制定了国家流感大流行防范的战略计划，包括在泰国制造流感疫苗的计划。在世界卫生组织的支持下，泰国政府医药组织（GPO）作为发展中国家的流感疫苗生产能力。GPO 生产的 H1N1 减毒活流感疫苗（LAIV）和 H5N2 LAIV 通过临床试验证明是安全和具有免疫原性的，随后获得了泰国食品药品监督管理局的大流行使用许可。GPO 生产的 H5N2 LAIV 已被证明对灭活亚单位 H5N1 加强疫苗具有启动作用。这家泰国本土制造商正在扩大其产能，以生产灭活流感疫苗（IIV），旨在为全国范围的流感疫苗生产提供可持续性。
